Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.
Case report
Pathologic collision
Small cell carcinoma
Urinary bladder cancer
Urothelial carcinoma
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
11 Jul 2023
11 Jul 2023
Historique:
received:
02
05
2023
accepted:
27
06
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
Urothelial carcinoma is a major subtype of bladder cancer and small cell carcinoma (SCC) is a rare type of cancer in clinical practice. Pathologic collision of urinary bladder urothelial carcinoma with SCC is not common in clinical settings. Here, we report a patient with high-grade papillary carcinoma which changed to collision tumor with SCC. The patient underwent radical cystectomy; however, neck and mediastinum lymph nodes metastases were detected 11 months after the operation. The lymph nodes were diagnosed pathologically as SCC. Chemoradiotherapy was subsequently prescribed. Unfortunately, this patient died of COVID-19 in early 2023. We hypothesized the mechanism underlying this pathological transformation. For patients with urothelial bladder cancer, pathological analysis should be conducted to allow standardized and persistent treatment. Moreover, drugs should be selected depending on the type of pathology, especially for patients who develop relapse, since collision tumor or other pathological tumors may be present. We recommend that radical cystectomy be performed early enough for patients with non-muscle invasive bladder cancer, who are at a high risk of tumor recurrence. However, this conclusion needs to be validated in a larger number of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Urothelial carcinoma is a major subtype of bladder cancer and small cell carcinoma (SCC) is a rare type of cancer in clinical practice. Pathologic collision of urinary bladder urothelial carcinoma with SCC is not common in clinical settings.
CASE PRESENTATION
METHODS
Here, we report a patient with high-grade papillary carcinoma which changed to collision tumor with SCC. The patient underwent radical cystectomy; however, neck and mediastinum lymph nodes metastases were detected 11 months after the operation. The lymph nodes were diagnosed pathologically as SCC. Chemoradiotherapy was subsequently prescribed. Unfortunately, this patient died of COVID-19 in early 2023.
DISCUSSION
CONCLUSIONS
We hypothesized the mechanism underlying this pathological transformation. For patients with urothelial bladder cancer, pathological analysis should be conducted to allow standardized and persistent treatment. Moreover, drugs should be selected depending on the type of pathology, especially for patients who develop relapse, since collision tumor or other pathological tumors may be present.
CONCLUSIONS
CONCLUSIONS
We recommend that radical cystectomy be performed early enough for patients with non-muscle invasive bladder cancer, who are at a high risk of tumor recurrence. However, this conclusion needs to be validated in a larger number of patients.
Identifiants
pubmed: 37434193
doi: 10.1186/s13000-023-01369-x
pii: 10.1186/s13000-023-01369-x
pmc: PMC10334510
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Informations de copyright
© 2023. The Author(s).
Références
Oncol Lett. 2021 Apr;21(4):305
pubmed: 33732381
Eur Urol. 2010 Aug;58(2):185-90
pubmed: 20303646
J Cancer. 2019 Oct 11;10(24):5891-5902
pubmed: 31762799
Eur Urol. 2020 Jan;77(1):101-109
pubmed: 31699526
Eur Urol. 2016 Feb;69(2):300-10
pubmed: 26346676
Oncol Rep. 2019 Apr;41(4):2181-2193
pubmed: 30816498
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
Cancers (Basel). 2021 May 20;13(10):
pubmed: 34065365
IJU Case Rep. 2020 Aug 05;3(6):252-256
pubmed: 33163917
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Int J Urol. 2018 Jan;25(1):7-17
pubmed: 28697535
World Neurosurg. 2018 Sep;117:137-141
pubmed: 29890277
Sci Rep. 2018 Apr 16;8(1):6044
pubmed: 29662235
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2019 Aug 30;11(9):
pubmed: 31480265
Int J Mol Sci. 2014 Oct 24;15(11):19330-41
pubmed: 25347272
Clin Genitourin Cancer. 2020 Aug;18(4):e450-e456
pubmed: 32146153
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Endourol. 2017 Aug;31(8):767-773
pubmed: 28557554
J Urol. 2019 Dec;202(6):1127-1135
pubmed: 31251717
Eur Urol Focus. 2018 Dec;4(6):880-888
pubmed: 28753872
Eur Urol. 2016 Jan;69(1):60-9
pubmed: 26210894
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Lancet. 2009 Jul 18;374(9685):239-49
pubmed: 19520422
Hum Pathol. 2018 Sep;79:57-65
pubmed: 29763719
Eur Urol. 2019 Oct;76(4):425-429
pubmed: 31303258
Clin Genitourin Cancer. 2017 Dec;15(6):e1095-e1106
pubmed: 28843376
Cureus. 2020 Apr 4;12(4):e7539
pubmed: 32377487